cardiovascular News
-
Transluminal Technologies Attends TCT, Announces Innovative Velox CD
Transluminal Technologies exhibits velox CD at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, ...
-
Leading cardiology clinics in Tampa roll out Coala Heart Monitor program
Tampa Cardiovascular Associates is one of the leading cardiovascular groups on the east coast of Florida. The physicians and employees of Tampa Cardiovascular Associates are committed to providing their patients with the best available programs for the prevention, diagnosis, and treatment of artery and vein diseases. The Coala Heart Monitor is now available for prescription at the multiple ...
-
Cardiovascular Implant Durability
Join me on the beautiful Monterey Coast at the Asilomar Conference Center for a unique and defining three-day conference focused on understanding, predicting, and optimizing the durability of cardiovascular implants. I’m talking on the second day about simulations and what we can learn from experimenting to increase confidence in predictions made with computational models. I’ll ...
By Echobio, LLC
-
Showcase
Zeneo® Adrenaline: A New Innovative Formulation
Anaphylactic shock is an absolute medical emergency. When anaphylactic shock is suspected, emergency services must be called and emergency first aid administered immediately. The only first-line treatment for anaphylactic shock is injectable adrenaline1. In the USA: 1.6% to 5.1% of the population has experienced anaphylactic shock, 1% of hospitalizations are caused by it, 0.1% of patients ...
By Crossject
-
Shockwave Medical to Participate in Two Upcoming Investor Conferences
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in two upcoming virtual investor conferences: The 2022 Wells Fargo Healthcare Conference Fireside Chat on Thursday, September 8, 2022, at 9:45 a.m. Eastern Time. The Morgan Stanley ...
-
Online clinic Medon collaborates with Longenesis to develop a cardiovascular disease risk calculator
In order to increase the public awareness of cardiovascular health and encourage the population to take preventive action by identifying and mitigating the effects of cardiovascular disease (CVD) risk factors in a timely fashion, the online clinic Medon in collaboration with the health technology start-up Longenesis, has published a survey to determine the CVD risk. After filling the survey, each ...
By Longenesis
-
Correcting and Replacing: Shockwave Medical to Participate in Two Upcoming Investor Conferences
In a release issued under the same headline on August 26, 2022, by Shockwave Medical, Inc. (NASDAQ: SWAV), please note that the fireside chat time for the Wells Fargo Healthcare Conference has been updated. The correct presentation time is 9:10 am Eastern Time. The details for the Morgan Stanley Healthcare Conference remain the same. The corrected release appears below: Shockwave Medical, Inc. ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with ...
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Oxford, UK – 29 March 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Tudorza®’s supplemental New Drug Application (sNDA) for the inclusion of unique new clinical data in the product’s ...
-
Genome Biologics Enters Into a Research Collaboration and Exclusive License Option Agreement with Leading Biopharmaceutical Company
Genome Biologics UG, Frankfurt, Germany, today announced that they have entered into a research collaboration with AstraZeneca related to screening of proteins of the human secretome able to drive cardiac regeneration and recovery in Myocardial Infarction (MI), Heart Failure (HF) and Cardiotoxicity (CT). Cardiovascular disease (CVD) remains the leading cause of death and disability globally, ...
-
Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programs for the prevention of cardiotoxicity and heart damage – an area of huge unmet need within the EU and globally
Genome Biologics UG, Frankfurt, Germany, today announced that they have been awarded up to 9.8 million euros of equity funding through the European Innovation Council (EIC) Accelerator program to accelerate their breakthrough innovations in cardiovascular drug discovery and development. Cardiovascular diseases account for the majority of mortality and disability globally, accounting for 32% of ...
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive ...
-
Visit Aktiedagen Lund September 26, and learn how ultrasound can be used to fight the world’s deadliest diseases
At Aktiedagen Lund on Monday 26 September 2022, AcouSort’s Commercial Director Agnes Michanek will talk about how AcouSort’s unique and validated ultrasound technology can be used in the fight against cardiovascular diseases, infections, and cancer – the three deadliest diseases in the world. AcouSort is at a very exciting stage in the company’s development with a growing ...
By AcouSort AB
-
Circassia Announces FDA Approval of Tudorza Supplemental New Drug Application
Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added to label – – Tudorza® is the only product in its class with these data in the label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US ...
-
IFEMA MADRID will held Heart Failure Congress in 2022
This announcement comes a few months after the ESC selected the Institution as host venue for its global congress for 2025, confirming the attractiveness of IFEMA MADRID and Madrid as a host city for large high-level medical congresses. The HFA comprises more than 10,000 members, and past Heart Failure congresses have hosted 5,500 to 6,000 delegates at their in-person editions. The ...
-
Thoma Bravo Completes Strategic Growth Investment in Circle Cardiovascular Imaging
Thoma Bravo, a leading software investment firm, today announced the completion of its strategic growth investment in Circle Cardiovascular Imaging Inc. ("Circle CVI"), the global leader in cardiovascular imaging solutions. Circle CVI is the leading provider of AI-based cardiac imaging and reporting solutions, including cardiac MRI ("CMR") and cardiac computerized tomography ("CT") imaging ...
-
Puzzle Medical Devices Inc. Wins TCT 2022 Shark Tank Innovation Competition
The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in ...
-
COVID-19 Statement From Reflow Medical
Reflow Medical is taking steps to prevent the community spread of COVID-19 and to ensure the safety of our employees. We are adapting to the changing environment as we continue to design and develop medical devices used in life-saving treatments for cardiovascular disease. We want to express our gratitude to those in the healthcare community, including our clinical partners, who are serving ...
-
Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior’s First-in-Class Heart Failure Program
Hanover, Germany, March 29, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 ...
-
The origin of domestic medical equipment need to encourage social capital to participate
Medical apparatus is a support for health services industries, and also can reflect a country's innovating ability. In recent years, China's medical equipment industry develop rapidly, annual sales reached CNY 200 billion in 2013. But behind the prosperity, China's medical equipment industry also faces a series of problems such as low level of science and technology innovation, high-end medical ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you